Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line
1998

Understanding Resistance to Topotecan in Ovarian Cancer Cells

publication Evidence: moderate

Author Information

Author(s): J Ma, M Maliepaard, K Nooter, WJ Loos, HJ Kolker, J Verweij, G Stoter, JHM Schellens

Primary Institution: Rotterdam Cancer Institute / University Hospital Rotterdam

Hypothesis

The study investigates the mechanisms of resistance to topotecan in a human ovarian cancer cell line.

Conclusion

The resistance of the IGROVT100r cell line to topotecan and SN-38 is primarily due to reduced drug accumulation, not related to topoisomerase I changes.

Supporting Evidence

  • The IGROVT100r cell line showed 29-fold resistance to topotecan and 51-fold resistance to SN-38.
  • Resistance was not due to changes in topoisomerase I protein levels or activity.
  • Accumulation of topotecan was significantly lower in the resistant cell line compared to the parental line.

Takeaway

Some cancer cells can become resistant to drugs like topotecan because they don't take in the drug properly, making it less effective.

Methodology

The study developed a topotecan-resistant ovarian cancer cell line and assessed drug accumulation and resistance patterns.

Statistical Information

P-Value

<0.001

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication